ZAMBELLI ALBERTO

Gaudio, M., Floreani, A., Schivardi, G., Alaimo, D., Basilico, V., Lorenzetti, I., et al. (2026). From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching. TUMORI, 112(1), 22-31 [10.1177/03008916251401048]. Detail

Provenzano, L., Dieci, M., Curigliano, G., Giuliano, M., Botticelli, A., Lambertini, M., et al. (2025). Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. ANNALS OF ONCOLOGY, 36(7 (July 2025)), 762-774 [10.1016/j.annonc.2025.03.023]. Detail

Lorini, L., Gili, R., Resteghini, C., Gerosa, R., Cecchi, L., Gurizzan, C., et al. (2025). Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer. ORAL ONCOLOGY, 164(May 2025) [10.1016/j.oraloncology.2025.107296]. Detail

Canzian, J., Gentile, D., De Sanctis, R., Jacobs, F., Benvenuti, C., Gaudio, M., et al. (2025). Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients. THE ONCOLOGIST, 30(5) [10.1093/oncolo/oyaf061]. Detail

Canzian, J., Conforti, F., Jacobs, F., Benvenuti, C., Gaudio, M., Gerosa, R., et al. (2025). Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses. CANCERS, 17(7) [10.3390/cancers17071054]. Detail